Literature DB >> 1577972

Oncogene expression in primary myelodysplasia: correlation with haematological, karyotypic, and clinical progression.

R M Hutchinson1, J H Pringle, S C Knight, I Lauder, A Potter, C Jagger.   

Abstract

AIMS: To see if the relative expressions of proto-oncogenes that are increased in acute myeloid leukaemia are raised in patients with myelodysplastic syndromes (MDS), and to see if they increase with progression to leukaemia. To note if there is a correlation between morphology, karyotype, and these proto-oncogene expressions and if any one proto-oncogene can predict prognosis.
METHOD: Bone marrow from 130 patients was analysed at six monthly intervals over two years for relative mRNA expression of seven oncogenes, karyotype, and morphology. The technique used slot blot hybridisation and densitometric analysis. The results were compared with 14 surgical controls and 30 people with vitamin deficiency anaemia.
RESULTS: Six of seven oncogenes showed increased expression which progressed with time, but did not correlate with morphological or karyotypic changes. Expression of four of the seven oncogenes was increased in megaloblastic and iron deficiency anaemia. C-mos showed differences among the five morphological subgroups; it correlated with abnormal location (p = 0.025) and seemed to influence prognosis.
CONCLUSION: Increased proto-oncogenes reflect the overall marrow perturbation in MDS. C-mos may reflect persistence of monocyte pathway which confirms marrow stability.

Entities:  

Mesh:

Year:  1992        PMID: 1577972      PMCID: PMC495276          DOI: 10.1136/jcp.45.4.339

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  32 in total

1.  [Decoding of the primary structure of the son3 region in human genome: identification of a new protein with unusual structure and homology with DNA-binding proteins].

Authors:  F B Berdichevskiĭ; I M Chumakov; L L Kiselev
Journal:  Mol Biol (Mosk)       Date:  1988 May-Jun

Review 2.  Interactions of oncogenes with haematopoietic cells.

Authors:  J H Pierce; A Eva; S A Aaronson
Journal:  Clin Haematol       Date:  1986-08

3.  Localization of the proto-oncogene MOS to 8q11-q12 by in situ chromosomal hybridization.

Authors:  J R Testa; N Z Parsa; M M Le Beau; G F Vande Woude
Journal:  Genomics       Date:  1988-07       Impact factor: 5.736

4.  Loss of ras oncogene mutation in a myelodysplastic syndrome after low-dose cytarabine therapy.

Authors:  D M Layton; G J Mufti; J Lyons; J W Janssen; C R Bartram
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

5.  Nuclear c-myc protein, maturation, and cell-cycle status of human haemopoietic cells.

Authors:  M A Bains; T G Hoy; P Baines; A Jacobs
Journal:  Br J Haematol       Date:  1987-11       Impact factor: 6.998

6.  The EcoRI RFLP of c-mos in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-geriatric controls.

Authors:  G Chenevix-Trench; M Southall; C Kidson
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

7.  Antisense myb inhibition of purified erythroid progenitors in development and differentiation is linked to cycling activity and expression of DNA polymerase alpha.

Authors:  M Valtieri; D Venturelli; A Caré; C Fossati; E Pelosi; C Labbaye; G Mattia; A M Gewirtz; B Calabretta; C Peschle
Journal:  Blood       Date:  1991-03-15       Impact factor: 22.113

Review 8.  Prognostic significance of chromosomal abnormalities in acute leukaemias and myelodysplastic syndromes.

Authors:  J J Yunis; R D Brunning
Journal:  Clin Haematol       Date:  1986-08

9.  Prognostic importance of hypodiploid hemopoietic precursors in myelodysplastic syndromes.

Authors:  R Clark; S Peters; T Hoy; S Smith; K Whittaker; A Jacobs
Journal:  N Engl J Med       Date:  1986-06-05       Impact factor: 91.245

10.  A threshold effect in the induction of tumorigenicity of an established human cell line by v-mos.

Authors:  B M O'Hara; D G Blair
Journal:  Oncogene       Date:  1988-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.